Although pulmonary fibrosis can occur in the absence of a clear‐cut inciting agent, and
without a clinically clear initial acute inflammatory phase, it is more commonly associated …

A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …

The molecular pathology of multi-organ injuries in COVID-19 patients remains unclear,
preventing effective therapeutics development. Here, we report a proteomic analysis of 144 …

A proportion of patients with certain types of interstitial lung disease (ILD), including chronic
hypersensitivity pneumonitis and ILDs associated with autoimmune diseases, develop a …

The transforming growth factor-β (TGF-β) signalling pathway is a key mediator of fibroblast
activation that drives the aberrant synthesis of extracellular matrix in fibrotic diseases. Here …

Idiopathic pulmonary fibrosis is a serious and progressive chronic lung disease that is
characterised by altered cellular composition and homoeostasis in the peripheral lung …

Continued elucidation of the mechanisms of hepatic fibrosis has yielded a comprehensive
and nuanced portrait of fibrosis progression and regression. The paradigm of hepatic …

Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …

MicroRNAs (miRNA) are small regulatory RNAs that control gene expression by
translational suppression and destabilization of target mRNAs. There is increasing evidence …

Abstract Fine particulate matter (PM2. 5) is the primary air pollutant that is able to induce
airway injury. Compelling evidence has shown the involvement of IL‐17A in lung injury …